Matches in SemOpenAlex for { <https://semopenalex.org/work/W611741358> ?p ?o ?g. }
Showing items 1 to 88 of
88
with 100 items per page.
- W611741358 endingPage "140" @default.
- W611741358 startingPage "136" @default.
- W611741358 abstract "With the purpose of investigating whether the 6-course standard dose treatment of etoposide-platinum (EP) in small cell lung cancer could be reduced to 4 courses without compromising patient's survival, 70 patients were randomized to receive either 4 or 6 cycles of etoposide 120 mg/m2 i.v. days 1-3 and cisplatin 80 mg/m2 day 1. With the intention of comparing these two durations as primary treatment policies, patients were randomized on admission and not after the fourth course. From the 69 evaluable patients 34 received EPx4 cycles and 35 EPx6 cycles. Objective response for EPx4 was achieved by 21 patients (62%, 95% CI 44%-78%) compared to 24 patients (69%, 95% CI 51%-83%) of the EPx6 group. Median times to progression were 6 mo (4-19) and 7 mo (4-40) respectively (P=0.06) in the two groups. Median survivals were 8.5 mo (4-28.5) and 9.5 mo (4-51) (p=0.04) respectively. No differences in the survival of limited-disease patients were shown with 10.5 mo (6-28.5) and 12 mo (8-51) respectively, in the two groups. Patients with extensive disease had a trend favoring prolonged chemotherapy with a median survival of 9 mo (5-16) versus 6.5 mo (4-16.5) for those in the EPx4 group (p=0.09). Toxicity was not significantly more severe in the EPx6 group. In conclusion, patients achieving complete response within 4 cycles may not need continued chemotherapy, but patients with extensive disease may benefit from 2 more cycles." @default.
- W611741358 created "2016-06-24" @default.
- W611741358 creator A5003533953 @default.
- W611741358 creator A5037805982 @default.
- W611741358 creator A5040223322 @default.
- W611741358 creator A5040393629 @default.
- W611741358 creator A5051477346 @default.
- W611741358 creator A5054375277 @default.
- W611741358 creator A5074407673 @default.
- W611741358 creator A5078850069 @default.
- W611741358 creator A5085535106 @default.
- W611741358 date "1998-01-01" @default.
- W611741358 modified "2023-10-18" @default.
- W611741358 title "Optimal Duration of Chemotherapy in Small Cell Lung Cancer: A Randomized Study of 4 versus 6 Cycles of Cisplatin-Etoposide" @default.
- W611741358 cites W1999960570 @default.
- W611741358 cites W2059422367 @default.
- W611741358 cites W2123767004 @default.
- W611741358 doi "https://doi.org/10.1179/joc.1998.10.2.136" @default.
- W611741358 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9603640" @default.
- W611741358 hasPublicationYear "1998" @default.
- W611741358 type Work @default.
- W611741358 sameAs 611741358 @default.
- W611741358 citedByCount "16" @default.
- W611741358 countsByYear W6117413582013 @default.
- W611741358 countsByYear W6117413582016 @default.
- W611741358 countsByYear W6117413582019 @default.
- W611741358 countsByYear W6117413582020 @default.
- W611741358 countsByYear W6117413582021 @default.
- W611741358 countsByYear W6117413582022 @default.
- W611741358 countsByYear W6117413582023 @default.
- W611741358 crossrefType "journal-article" @default.
- W611741358 hasAuthorship W611741358A5003533953 @default.
- W611741358 hasAuthorship W611741358A5037805982 @default.
- W611741358 hasAuthorship W611741358A5040223322 @default.
- W611741358 hasAuthorship W611741358A5040393629 @default.
- W611741358 hasAuthorship W611741358A5051477346 @default.
- W611741358 hasAuthorship W611741358A5054375277 @default.
- W611741358 hasAuthorship W611741358A5074407673 @default.
- W611741358 hasAuthorship W611741358A5078850069 @default.
- W611741358 hasAuthorship W611741358A5085535106 @default.
- W611741358 hasConcept C126322002 @default.
- W611741358 hasConcept C141071460 @default.
- W611741358 hasConcept C168563851 @default.
- W611741358 hasConcept C2776178081 @default.
- W611741358 hasConcept C2776256026 @default.
- W611741358 hasConcept C2776694085 @default.
- W611741358 hasConcept C2777714996 @default.
- W611741358 hasConcept C2778119113 @default.
- W611741358 hasConcept C2778239845 @default.
- W611741358 hasConcept C2778822529 @default.
- W611741358 hasConcept C29730261 @default.
- W611741358 hasConcept C71924100 @default.
- W611741358 hasConcept C90924648 @default.
- W611741358 hasConceptScore W611741358C126322002 @default.
- W611741358 hasConceptScore W611741358C141071460 @default.
- W611741358 hasConceptScore W611741358C168563851 @default.
- W611741358 hasConceptScore W611741358C2776178081 @default.
- W611741358 hasConceptScore W611741358C2776256026 @default.
- W611741358 hasConceptScore W611741358C2776694085 @default.
- W611741358 hasConceptScore W611741358C2777714996 @default.
- W611741358 hasConceptScore W611741358C2778119113 @default.
- W611741358 hasConceptScore W611741358C2778239845 @default.
- W611741358 hasConceptScore W611741358C2778822529 @default.
- W611741358 hasConceptScore W611741358C29730261 @default.
- W611741358 hasConceptScore W611741358C71924100 @default.
- W611741358 hasConceptScore W611741358C90924648 @default.
- W611741358 hasIssue "2" @default.
- W611741358 hasLocation W6117413581 @default.
- W611741358 hasLocation W6117413582 @default.
- W611741358 hasOpenAccess W611741358 @default.
- W611741358 hasPrimaryLocation W6117413581 @default.
- W611741358 hasRelatedWork W1974008536 @default.
- W611741358 hasRelatedWork W2006516489 @default.
- W611741358 hasRelatedWork W2017316579 @default.
- W611741358 hasRelatedWork W2040572070 @default.
- W611741358 hasRelatedWork W2060566124 @default.
- W611741358 hasRelatedWork W2427407971 @default.
- W611741358 hasRelatedWork W2471039675 @default.
- W611741358 hasRelatedWork W3143052495 @default.
- W611741358 hasRelatedWork W4229812857 @default.
- W611741358 hasRelatedWork W8414141 @default.
- W611741358 hasVolume "10" @default.
- W611741358 isParatext "false" @default.
- W611741358 isRetracted "false" @default.
- W611741358 magId "611741358" @default.
- W611741358 workType "article" @default.